ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
37K |
17 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
37K
|
17
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
37K |
19 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
37K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
37K |
6 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
37K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
37K |
6 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
37K
|
6
|
|
ASX - By Stock
|
PAR |
Resolution of lumbar bone marrow oedema
|
|
adherent
|
76 |
37K |
90 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
37K
|
90
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
32 |
09/05/22 |
09/05/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
32
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
adherent
|
36 |
13K |
1 |
30/04/22 |
30/04/22 |
ASX - By Stock
|
36
|
13K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
adherent
|
36 |
13K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
36
|
13K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
adherent
|
36 |
13K |
47 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
36
|
13K
|
47
|
|
ASX - By Stock
|
PAR |
Re:
Ann: FDA Grants Paradigm Fast Track Designation For OA
|
|
adherent
|
88 |
42K |
16 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
88
|
42K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
PAR 2022 and beyond
|
|
adherent
|
25 |
12K |
0 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
25
|
12K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
adherent
|
59 |
27K |
2 |
11/03/22 |
11/03/22 |
ASX - By Stock
|
59
|
27K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
adherent
|
59 |
27K |
23 |
11/03/22 |
11/03/22 |
ASX - By Stock
|
59
|
27K
|
23
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
adherent
|
59 |
27K |
36 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
59
|
27K
|
36
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
adherent
|
59 |
27K |
19 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
59
|
27K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
iPPS and Long Covid, but first a Prologue & story...
|
|
adherent
|
18 |
7.1K |
5 |
05/03/22 |
05/03/22 |
ASX - By Stock
|
18
|
7.1K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
iPPS and Long Covid, but first a Prologue & story...
|
|
adherent
|
18 |
7.1K |
2 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
18
|
7.1K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
iPPS and Long Covid, but first a Prologue & story...
|
|
adherent
|
18 |
7.1K |
8 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
18
|
7.1K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
PAR General discussion
|
|
adherent
|
339 |
141K |
16 |
22/01/22 |
22/01/22 |
ASX - By Stock
|
339
|
141K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
PAR General discussion
|
|
adherent
|
339 |
141K |
13 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
339
|
141K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Preliminary Results from Phase 2 MPS I Study
|
|
adherent
|
26 |
11K |
2 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
26
|
11K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
PAR General discussion
|
|
adherent
|
339 |
141K |
5 |
09/11/21 |
09/11/21 |
ASX - By Stock
|
339
|
141K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
PAR General discussion
|
|
adherent
|
339 |
141K |
10 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
339
|
141K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Pre approval marketing has begun.
|
|
adherent
|
29 |
11K |
9 |
12/10/21 |
12/10/21 |
ASX - By Stock
|
29
|
11K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Anticoagulant discussion
|
|
adherent
|
3 |
1.2K |
5 |
28/09/21 |
28/09/21 |
ASX - By Stock
|
3
|
1.2K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
PAR and back pain
|
|
adherent
|
6 |
3.1K |
21 |
09/09/21 |
09/09/21 |
ASX - By Stock
|
6
|
3.1K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
1 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
4.4K
|
2.0M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
1 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
4.4K
|
2.0M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
2 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
4.4K
|
2.0M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
4 |
11/08/21 |
11/08/21 |
ASX - By Stock
|
4.4K
|
2.0M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
5 |
11/08/21 |
11/08/21 |
ASX - By Stock
|
4.4K
|
2.0M
|
5
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
adherent
|
4.4K |
2.0M |
3 |
11/08/21 |
11/08/21 |
ASX - By Stock
|
4.4K
|
2.0M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM REPORTS IND APPLICATION UPDATE
|
|
adherent
|
150 |
61K |
23 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
150
|
61K
|
23
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
adherent
|
318 |
138K |
1 |
02/08/21 |
02/08/21 |
ASX - By Stock
|
318
|
138K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Where are PAR shareholders located?
|
|
adherent
|
115 |
29K |
4 |
01/08/21 |
01/08/21 |
ASX - By Stock
|
115
|
29K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Where are PAR shareholders located?
|
|
adherent
|
115 |
29K |
1 |
31/07/21 |
31/07/21 |
ASX - By Stock
|
115
|
29K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Trial
|
|
adherent
|
16 |
6.3K |
10 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
16
|
6.3K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Trial
|
|
adherent
|
16 |
6.3K |
12 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
16
|
6.3K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
6 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
389
|
124K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
13 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
389
|
124K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
9 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
389
|
124K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
36 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
389
|
124K
|
36
|
|
ASX - By Stock
|
PAR |
Re:
The miracles of iPPS on MPS and a super bonus.
|
|
adherent
|
64 |
19K |
12 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
64
|
19K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
The miracles of iPPS on MPS and a super bonus.
|
|
adherent
|
64 |
19K |
4 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
64
|
19K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
The miracles of iPPS on MPS and a super bonus.
|
|
adherent
|
64 |
19K |
5 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
64
|
19K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
The miracles of iPPS on MPS and a super bonus.
|
|
adherent
|
64 |
19K |
20 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
64
|
19K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
40 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
124K
|
40
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
4 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
124K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
14 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
124K
|
14
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
adherent
|
389 |
124K |
51 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
124K
|
51
|
|